CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Shannon L. Maude(Children's Hospital of Philadelphia), Stephan A. Grupp(Children's Hospital of Philadelphia)
Cited by 718
Related Papers
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
|Nature Reviews Clinical Oncology|2022|324
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction
|Cancer Discovery|2020|297
FOXO1 is a master regulator of memory programming in CAR T cells
|Nature|2024|189